The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
Open accessAbstract
A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a phase 2b efficacy study in humans. Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref. 3). Here we show that an improved T-cell-based vaccine regimen using two serologically distinct adenovirus vectors afforded substantially improved protective efficacy in this challenge model. In particular, a heterologous rAd26 prime/rAd5 boost vaccine regimen expressing SIV Gag elicited cellular immune responses with augmented magnitude, breadth and polyfunctionality as compared with the homologous rAd5 regimen. After SIVMAC251 challenge, monkeys vaccinated with the rAd26/rAd5 regimen showed a 1.4 log reduction of peak and a 2.4 log reduction of setpoint viral loads as well as decreased AIDS-related mortality as compared with control animals. These data demonstrate that durable partial immune control of a pathogenic SIV challenge for more than 500 days can be achieved by a T-cell-based vaccine in Mamu-A*01-negative rhesus monkeys in the absence of a homologous Env antigen. These findings have important implications for the development of next-generation T-cell-based vaccine candidates for HIV-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
Betts, M. R. (2006) · Blood · doi:10.1182/blood-2005-12-4818 · Cited by 1,826
Veazey, R. S., DeMaria, M., Chalifoux, L. V., Shvetz, D. E., Pauley, D. R., Knight, H. L., Rosenzweig, M., Johnson, R. P., Desrosiers, R. C., & Lackner, A. A. (1998) · Science · doi:10.1126/science.280.5362.427 · Cited by 1,407
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major
Darrah, P. A., Patel, D. T., De Luca, P. M., Lindsay, R. W. B., Davey, D. F., Flynn, B. J., Hoff, S. T., Andersen, P., Reed, S. G., Morris, S. L., et al. (2007) · Nature Medicine · doi:10.1038/nm1592 · Cited by 1,378
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection
Mattapallil, J. J., Douek, D. C., Hill, B., Nishimura, Y., Martin, M., & Roederer, M. (2005) · Nature · doi:10.1038/nature03501 · Cited by 1,278
Shiver, J. W., Fu, T.-M., Chen, L., Casimiro, D. R., Davies, M.-E., Evans, R. K., Zhang, Z.-Q., Simon, A. J., Trigona, W. L., Dubey, S. A., et al. (2002) · Nature · doi:10.1038/415331a · Cited by 1,176
Self-citationCD8+ T-cell responses to different HIV proteins have discordant associations with viral load
Kiepiela, P., Ngumbela, K., Thobakgale, C., Ramduth, D., Honeyborne, I., Moodley, E., Reddy, S., de Pierres, C., Mncube, Z., Mkhwanazi, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1520 · Cited by 1,032
Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells
Li, Q., Duan, L., Estes, J. D., Ma, Z.-M., Rourke, T., Wang, Y., Reilly, C., Carlis, J., Miller, C. J., & Haase, A. T. (2005) · Nature · doi:10.1038/nature03513 · Cited by 952
Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays
Montefiori, D. C. (2004) · Current Protocols in Immunology · doi:10.1002/0471142735.im1211s64 · Cited by 580
Self-citationAbbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02696-06 · Cited by 503
Self-citationDevelopment and Homeostasis of T Cell Memory in Rhesus Macaque
Pitcher, C. J., Hagen, S. I., Walker, J. M., Lum, R., Mitchell, B. L., Maino, V. C., Axthelm, M. K., & Picker, L. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.1.29 · Cited by 467
Cited by
The immune response during acute HIV-1 infection: clues for vaccine development
McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N., & Haynes, B. F. (2010) · Nature Reviews Immunology · doi:10.1038/nri2674 · Cited by 871
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
“Adenoviral vaccine regimens based upon sequential exposure to HIV antigens and/or different serotypes (techniques suggested to induce more profound T-cell responses) then became the focus of investigation in subsequent years.(151,198) An NIH-sponsored phase II clinical trial (called the “HVTN trial”) began in 2009 and…”
BackgroundHansen, S. G., Vieville, C., Whizin, N., Coyne-Johnson, L., Siess, D. C., Drummond, D. D., Legasse, A. W., Axthelm, M. K., Oswald, K., Trubey, C. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1935 · Cited by 675
Cohen, M. S., Shaw, G. M., McMichael, A. J., & Haynes, B. F. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011874 · Cited by 660
Barouch, D. H., Whitney, J. B., Moldt, B., Klein, F., Oliveira, T. Y., Liu, J., Stephenson, K. E., Chang, H.-W., Shekhar, K., Gupta, S., et al. (2013) · Nature · doi:10.1038/nature12744 · Cited by 644
Self-citationGoonetilleke, N., Liu, M. K. P., Salazar-Gonzalez, J. F., Ferrari, G., Giorgi, E., Ganusov, V. V., Keele, B. F., Learn, G. H., Turnbull, E. L., Salazar, M. G., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090365 · Cited by 641
Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys
Whitney, J. B., Hill, A. L., Sanisetty, S., Penaloza-MacMaster, P., Liu, J., Shetty, M., Parenteau, L., Cabral, C., Shields, J., Blackmore, S., et al. (2014) · Nature · doi:10.1038/nature13594 · Cited by 629
Self-citationVaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
Barouch, D. H., Liu, J., Li, H., Maxfield, L. F., Abbink, P., Lynch, D. M., Iampietro, M. J., SanMiguel, A., Seaman, M. S., Ferrari, G., et al. (2012) · Nature · doi:10.1038/nature10766 · Cited by 465
Self-citationMosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys
Barouch, D. H., O'Brien, K. L., Simmons, N. L., King, S. L., Abbink, P., Maxfield, L. F., Sun, Y.-H., La Porte, A., Riggs, A. M., Lynch, D. M., et al. (2010) · Nature Medicine · doi:10.1038/nm.2089 · Cited by 384
Self-citationDiversity in T Cell Memory: An Embarrassment of Riches
Jameson, S. C., & Masopust, D. (2009) · Immunity · doi:10.1016/j.immuni.2009.11.007 · Cited by 382
A Blueprint for HIV Vaccine Discovery
Burton, D. R., Ahmed, R., Barouch, D. H., Butera, S. T., Crotty, S., Godzik, A., Kaufmann, D. E., McElrath, M. J., Nussenzweig, M. C., Pulendran, B., et al. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.09.008 · Cited by 375
Self-citationViruses as vaccine vectors for infectious diseases and cancer
Draper, S. J., & Heeney, J. L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2240 · Cited by 353
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Haynes, B. F., Wiehe, K., Borrow, P., Saunders, K. O., Korber, B., Wagh, K., McMichael, A. J., Kelsoe, G., Hahn, B. H., Alt, F., et al. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00753-w · Cited by 352
Barouch, D. H., Stephenson, K. E., Borducchi, E. N., Smith, K., Stanley, K., McNally, A. G., Liu, J., Abbink, P., Maxfield, L. F., Seaman, M. S., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.061 · Cited by 342
Self-citationMilligan, I. D., Gibani, M. M., Sewell, R., Clutterbuck, E. A., Campbell, D., Plested, E., Nuthall, E., Voysey, M., Silva-Reyes, L., McElrath, M. J., et al. (2016) · JAMA · doi:10.1001/jama.2016.4218 · Cited by 324
Self-citationEarly Events in Sexual Transmission of HIV and SIV and Opportunities for Interventions
Haase, A. T. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-080709-124959 · Cited by 321
Barouch, D. H., Kik, S. V., Weverling, G. J., Dilan, R., King, S. L., Maxfield, L. F., Clark, S., Ng’ang’a, D., Brandariz, K. L., Abbink, P., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.025 · Cited by 305
Self-citationColloca, S., Barnes, E., Folgori, A., Ammendola, V., Capone, S., Cirillo, A., Siani, L., Naddeo, M., Grazioli, F., Esposito, M. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002925 · Cited by 300
Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys
Barouch, D. H., Alter, G., Broge, T., Linde, C., Ackerman, M. E., Brown, E. P., Borducchi, E. N., Smith, K. M., Nkolola, J. P., Liu, J., et al. (2015) · Science · doi:10.1126/science.aab3886 · Cited by 297
Self-citationIdoyaga, J., Lubkin, A., Fiorese, C., Lahoud, M. H., Caminschi, I., Huang, Y., Rodriguez, A., Clausen, B. E., Park, C. G., Trumpfheller, C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019547108 · Cited by 287
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
Ewer, K. J., O’Hara, G. A., Duncan, C. J. A., Collins, K. A., Sheehy, S. H., Reyes-Sandoval, A., Goodman, A. L., Edwards, N. J., Elias, S. C., Halstead, F. D., et al. (2013) · Nature Communications · doi:10.1038/ncomms3836 · Cited by 286
Accelerating Next-Generation Vaccine Development for Global Disease Prevention
Koff, W. C., Burton, D. R., Johnson, P. R., Walker, B. D., King, C. R., Nabel, G. J., Ahmed, R., Bhan, M. K., & Plotkin, S. A. (2013) · Science · doi:10.1126/science.1232910 · Cited by 282
Fischer, W., Ganusov, V. V., Giorgi, E. E., Hraber, P. T., Keele, B. F., Leitner, T., Han, C. S., Gleasner, C. D., Green, L., Lo, C.-C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012303 · Cited by 284
Mast, T. C., Kierstead, L., Gupta, S. B., Nikas, A. A., Kallas, E. G., Novitsky, V., Mbewe, B., Pitisuttithum, P., Schechter, M., Vardas, E., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2009.10.145 · Cited by 276
Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys
Borducchi, E. N., Cabral, C., Stephenson, K. E., Liu, J., Abbink, P., Ng’ang’a, D., Nkolola, J. P., Brinkman, A. L., Peter, L., Lee, B. C., et al. (2016) · Nature · doi:10.1038/nature20583 · Cited by 276
Self-citationNew Insights on Adenovirus as Vaccine Vectors
Lasaro, M. O., & Ertl, H. C. (2009) · Molecular Therapy · doi:10.1038/mt.2009.130 · Cited by 263
Flatz, L., Roychoudhuri, R., Honda, M., Filali-Mouhim, A., Goulet, J.-P., Kettaf, N., Lin, M., Roederer, M., Haddad, E. K., Sékaly, R. P., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013084108 · Cited by 91
Implications of the Innate Immune Response to Adenovirus and Adenoviral Vectors
Gregory, S. M., Nazir, S. A., & Metcalf, J. P. (2011) · Future Virology · doi:10.2217/fvl.11.6 · Cited by 89
“Also, chimeric vectors that display a combination of AdV capsid proteins from multiple AdV serotypes are in development [220–227].”
BackgroundBarnett, S. W., Burke, B., Sun, Y., Kan, E., Legg, H., Lian, Y., Bost, K., Zhou, F., Goodsell, A., zur Megede, J., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02533-09 · Cited by 82
Immune memory: the basics and how to trigger an efficient long-term immune memory
Beverley, P. C. L. (2010) · Journal of Comparative Pathology · doi:10.1016/j.jcpa.2009.09.008 · Cited by 4
Metadata
- Authors
- Liu, J., O’Brien, K. L., Lynch, D. M., Simmons, N. L., La Porte, A., Riggs, A. M., Abbink, P., Coffey, R. T., Grandpre, L. E., Seaman, M. S., Landucci, G., Forthal, D. N., Montefiori, D. C., Carville, A., Mansfield, K. G., Havenga, M. J., Pau, M. G., Goudsmit, J., & Barouch, D. H.
- Venue
- Nature
- Published
- 2008-11-09
- Volume
- 457
- Issue
- 7225
- Pages
- 87-91
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2151130810
- Cited by
- 452
- References
- 26
- FWCI
- 23.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.